

Anti-NGAL (human)**Mouse monoclonal antibody, biotinylated**

Subclass: IgG2a/k

PRODUCT NO.

ABS 062-14 B

Clone: 14

SPECIFICITY	ABS 062-14 is specific for human NGAL (neutrophil gelatinase-associated lipocalin)
IMMUNOGEN	Human recombinant NGAL coupled to carrier
TESTED APPLICATIONS	ELISA
SPECIES REACTIVITY (POSITIVE)	Human
SPECIES REACTIVITY (NEGATIVE)	Not determined
EPITOPE SPECIFICITY	Differs from those of HYB 211-01, the ABS 038 series of antibodies and ABS 062-33.

PRESENTATION	
Content:	50 µL, 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Preparation:	Biotinylated
Form:	Liquid
Solvent:	0.01 M phosphate buffer, pH 7.4, with 0.14 M NaCl and 15 mM sodium azide
Storage:	4-8°C without exposure to light. No precautions necessary during handling.

APPLICATION **ELISA:** When ABS 062-14 is used as biotinylated detection antibody with ABS 062-33 as capture antibody, the assay is specific for NGAL monomer, cross-reacting <1% with NGAL homodimer.

TARGET Neutrophil gelatinase-associated lipocalin (NGAL; also called lipocalin 2, siderocalin and neutrophil lipocalin) is a member of the lipocalin family of proteins which bind and transport small lipophilic molecules. NGAL is released by activated neutrophils and occurs as 25-kDa glycosylated single protein chain monomers, which form dimers and small amounts of higher oligomers, as well as complexes with matrix metalloproteinase 9 (MMP-9; gelatinase B). Low level expression of NGAL in a variety of epithelia may be increased in inflammation or cancers. Expression of NGAL in the kidney is dramatically increased by acute kidney injury.

REFERENCES**CONDITIONS**

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.